Todd Barron, MD
Neurology with Special Qualifications in Child Neurology · Manchester, PANPI 1215967518
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Medtronic at 26.6% of the total. Reporting peaked in 2024 at $434 and has fallen 60.8% since, to $170 in 2025. That places this record below the midpoint for neurology with special qualifications in child neurology clinicians in PA, where the typical reported total is $761.
Across 14 payments — averaging $46.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$173
- Conmed Corporation$166
- Boston Scientific$91
- AbbVie$63
- UCB, Inc.$57
- Livanova USA, Inc.$55
- plus $44 from 2 others
Across 83 payments — averaging $4238.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$233K
- GW Research Limited$74K
- Zogenix Inc.$44K
What the payments were for
- Food & beverage$647100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $173 |
| Conmed Corporation | 1 | $166 |
| Boston Scientific | 1 | $91 |
| AbbVie | 3 | $63 |
| UCB, Inc. | 2 | $57 |
| Livanova USA, Inc. | 2 | $55 |
| Covidien LP | 1 | $42 |
| Travere Therapeutics, Inc. | 2 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CONMED BILIARY$166
- ProdiGI$153
How this compares
$648 in reported general payments places this provider in the 45th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.
See all neurology with special qualifications in child neurology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 62 | $525,727 |
| FinteplaFenfluramine Hcl | 11 | $194,624 |
| XcopriCenobamate | 102 | $164,410 |
| Everolimus | 14 | $128,607 |
| OnfiClobazam | 19 | $78,009 |
| AptiomEslicarbazepine Acetate | 30 | $75,090 |
| LamictalLamotrigine | 42 | $39,267 |
| NayzilamMidazolam | 38 | $37,498 |
| BriviactBrivaracetam | 19 | $31,490 |
| FycompaPerampanel | 26 | $31,372 |
| Lamictal XrLamotrigine | 24 | $30,095 |
| VimpatLacosamide | 15 | $13,583 |
| Lamictal OdtLamotrigine | 14 | $12,645 |
| Lacosamide | 54 | $11,332 |
| ValtocoDiazepam | 13 | $9,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Nayzilam, Briviact, Vimpat | $57 | $277,19583 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.
Other neurology with special qualifications in child neurology in Manchester
- Jeremy TimothyManchester$544
- Anne MorseDanville$582K
- John BrandsemaPhiladelphia$526K
- Susan MatesanzPhiladelphia$138K
- Elizabeth KichulaPhiladelphia$90K
- Dennis DlugosPhiladelphia$88K
- Alexandra KornbluhPhiladelphia$88K
- Nicholas AbendPhiladelphia$56K
- Sabrina YumPhiladelphia$33K
- Eric MarshPhiladelphia$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.